Ambronaff Syrup

Ambronaff is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambronaff stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambronaff stimulates production of phospholipids of surfactant by alveolar cells. Ambronaff has anti-inflammatory properties. In patients with COPD, it improves airway patency. Beside these, Ambronaff also exhibits anti-oxidant activity. Long-term use is possible because of the good tolerability of the preparation.

Uses

  • • Acute and chronic diseases of respiratory tracts associated with viscid mucus including acute and chronic bronchitis
  • • Productive cough
  • • Inflammatory diseases of Rhinopharyngeal tract (e.g. Laryngitis, Pharyngitis, Sinusitis and Rhinitis) associated with viscid mucus
  • • Asthmatic bronchitis, Bronchial asthma with difficult departure of mucus
  • • Bronchiectasis
  • • Chronic pneumonia.

Ambronaff is also used to associated treatment for these conditions: Airway secretion clearance therapy

Trade Name Ambronaff
Generic Ambroxol
Other Names Ambroxol, Ambroxolum, Bisolvon metabolite vIII, Bromhexine metabolite vIII, Bromhexine-metabolite vIII
Weight 15mg/5ml
Type Syrup
Formula C13H18Br2N2O
Weight Average: 378.108
Monoisotopic: 375.978589
Protein binding

Approximately 90%

Therapeutic Class Cough expectorants & mucolytics
Manufacturer Naafco Pharma Ltd
Available Country Bangladesh
Last Updated: June 23, 2021 at 11:16 am

Dosage

Ambronaff dosage

Average daily dose (preferably after meal):Pediatric Drops: 

  • 0-6 months: 0.5 ml 2 times a day
  • 6-12 months: 1 ml 2 times a day
  • 1-2 years: 1.25 ml 2 times a day

Syrup: 

  • 2-5 years: 2.5 ml (1/2 teaspoonful) 2-3 times a day
  • 5-10 years: 5 ml (1 teaspoonful) 2-3 times a day
  • 10 years and adults: 10 ml (2 teaspoonful) 3 times a day.

Sustained release capsule: 

  • Adult and children over 12 years old: 1 capsule once daily

Specific application features: Ambronaff may be prescribed to patients suffering from diabetes mellitus.

Side Effects

Gastrointestinal side-effects like epigastric pain, gastric fullness may occur occasionally. Rarely allergic responses such as eruption, urticaria or angioneurotic edema may occur.

Precaution

Ambronaff should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.

Interaction

Ambronaff has no interaction with cardioactive glycosides, corticosteroids, bronchodilators, diuretics and antibiotics (normally used in the treatment of bronchopulmonary affections). But Ambronaff should not be taken simultaneously with antitussives (e.g. Codeine) because mucus, which has been liquefied by Ambronaff, might not be expectorated.

Half Life

7-12 hours

Pregnancy & Breastfeeding use

Pregnancy: Teratogenic and fetal toxicity studies have shown no harmful effect of Ambronaff. However, it is advised not to use during pregnancy, especially in the 1st trimester.

Lactation: Safety during lactation has not been established.

Contraindication

Contraindicated in known hypersensitivity to Ambronaff or Bromhexine.

Interaction with other Medicine

Ambronaff has no interaction with cardioactive glycosides, corticosteroids, bronchodilators, diuretics and antibiotics (normally used in the treatment of bronchopulmonary affections). But Ambronaff should not be taken simultaneously with antitussives (e.g. Codeine) because mucus, which has been liquefied by Ambronaff, might not be expectorated.

Ambronaff contains Ambroxol see full prescribing information from innovator Monograph